Why the study?
Does short-term amiodarone therapy cause early-onset pulmonary toxicity in patients with post-myocardial infarction ventricular tachycardia?
Does short-term amiodarone therapy cause early-onset pulmonary toxicity in patients with post-myocardial infarction ventricular tachycardia?
Amiodarone-induced pulmonary toxicity can occur very early after treatment initiation, highlighting the need for clinical vigilance even with short-term use.
Answers are grounded in this paper and cite their sources.
May warrant vigilance for early amiodarone toxicity even with short courses; single case leaves open monitoring needs in post-MI VT.
Amiodarone is a widely used antiarrhythmic agent. Among its various adverse effects, amiodarone-induced pulmonary toxicity (APT) is the most life threatening complication, which has been described mostly in patients who have been in treatment with high accumulative doses for a long duration of time. However, amiodarone therapy in short-term duration induced APT was rarely reported. We describe a case of a 54-year-old man who is presented with symptoms of APT after a few days of therapy for post-myocardial infarction ventricular tachycardia. For early diagnosis and successful treatment, awareness and high suspicion of this rare type of early onset APT is crucial in patients with amiodarone therapy.
No takes yet. Share an insight, caveat, or question.
Lee et al. (2013) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: